Sustainability
A global pioneer in the development of new drugs
Recognition
SK Biopharmaceuticals strategically promotes global ESG management through actively responding to ESG evaluation and participating in related initiatives.
-
AAA
-
Integrated A
(Environmental A, Social A,
Governance A) -
Recognized as a
Sustainability Yearbook Member
and included in the DJSI Korea Index
for the 4th consecutive year -
Included in the Index for the
3rd consecutive year -
Medium Risk Grade
-
AAA
-
Integrated A
(Environmental B+, Social A+,
Governance A) -
Included in the DJSI Korea Index
for the 3rd consecutive year -
Included in the Index for the
2nd consecutive year -
Medium Risk Grade
-
AA
-
Integrated A
(Environmental B+, Social A+,
Governance A) -
Included in the DJSI Korea Index
for the 2nd consecutive year -
Included in the Index
for the first time
-
BBB
-
Integrated A
(Environmental B+, Social A,
Governance A) -
Included in the DJSI Korea Index
for the first time
Participating Initiatives
SK Biopharmaceuticals fulfills the management standards expected by the international community through
participation in various global initiatives and contributes to building a sustainable business ecosystem.
-
United Nations Global Compact (UNGC)A global initiative that promotes responsible corporate management and sustainable growth based on the Ten Principles concerning human rights, labor, the environment, and anti-corruption.
-
Pharmaceutical Supply Chain Initiative (PSCI)An initiative that promotes responsible supply chain operations by disseminating standards for ethics, labor, safety, environment, and management systems across the pharmaceutical and healthcare supply chain.
-
Rx-360A global pharmaceutical supply chain consortium that shares supply chain audit results, guidelines, and best practices to strengthen quality and patient safety across the pharmaceutical supply chain.